367500-72-9

Upstream product

• 367500-88-7 4-hydroxy-[1,4']bipiperidinyl-1'-carboxylic acid tert-butyl ester 
• 107-83-5 2-Methylpentane 
• 1435-49-0 3,4-dichlorofluorobenzene 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 95-77-2 3,4-dichlorophenol 
• 260441-48-3 tert-Butyl 4-(3,4-dichlorophenoxy)-1-piperidinecarboxylate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 245057-73-2 4-(3,4-dichloro-phenoxy)-piperidine 

Downstream Products

• 367500-74-1 4-(3,4-dichloro-phenoxy)-[1,4']bipiperidine 
• 1413286-14-2 C₂₄H₂₆Cl₂N₆O₂ 
• 1413286-15-3 C₂₇H₃₂Cl₂N₂O₆S 
• 1413286-16-4 C₂₆H₃₁Cl₂N₃O₄ 
• 1413286-17-5 C₂₉H₃₄Cl₂N₆O₄ 
• 367497-18-5 C₂₅H₂₈Cl₂N₂O₅ 
• 1413286-11-9 C₂₄H₂₆Cl₂N₂O₄ 
• 1413286-12-0 C₂₄H₂₆Cl₂N₂O₄ 
• 1413286-13-1 C₂₅H₂₆Cl₂N₄O₄ 
• 485391-81-9 C₂₃H₂₇Cl₂N₃O₄S 

Relevant academic research and scientific papers

The discovery of CCR3/H1 dual antagonists with reduced hERG risk

A series of dual CCR3/H1 antagonists based on a bispiperidine scaffold were discovered. Introduction of an acidic group overcame hERG liability. Bioavailability was optimised by modulation of physico-chemical properties and physical form to del

Chemical compounds

The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.